logo
‘Everyone cried': Paralysed woman describes walking after pioneering treatment

‘Everyone cried': Paralysed woman describes walking after pioneering treatment

Yahoo24-02-2025

A woman who was paralysed as a result of an illness has described how 'everybody cried' when she was able to take her first steps following a pioneering treatment.
Claire Trivedi received a type of spinal cord stimulation during a small clinical trial which enabled her to take a few steps using a walker.
The 48-year-old from London was paralysed from the waist down in 2017 when a group of abnormal blood vessels in her spinal cord burst.
The mother of two is one of 10 spinal cord injury patients who took part in a study assessing new stimulation technology.
While taking part in the trial, she was able to restore some functions which were initially thought to be lost after her injury.
The technology has been described as a 'hearing aid for the nervous system' and works by stimulating the 'dormant' spine below the patient's injury, combined with 'activity-based therapy'.
Experts said the results of the small pilot study were 'game changing'.
And Spinal Research chairwoman Tara Stewart said the study suggests 'it's now time to stop talking about spinal cord injury as being incurable'.
Ten people aged between 21 and 68 with different levels of spinal cord injuries took part in the study, which has been published in the journal Neuromodulation: Technology At Neural Interface.
All participants in the Pathfinder 2 trial, funded by Spinal Research, made significant improvements in their upper body strength, trunk control and balance.
And some saw major gains in hand grip and dexterity and lower body functions after using Onward Medical's ARC-EX Therapy combined with rehabilitation.
Patients took part in the study for more than a year at Neurokinex rehabilitation facilities in the UK and each had 120 sessions where they were given transcutaneous spinal cord stimulation.
The technology delivers electrical pulses through the skin to stimulate the spinal cord which means that signals weakened or interrupted by a spinal cord injury can drive movement.
It is coupled with intensive physical therapy, tailored to each patient.
Some of those who took part in the trial saw bodily function return a decade after injury or illness.
Researchers said that the improvements did not plateau, which suggests further benefits may be achieved with extended treatment.
Ms Trivedi said: 'I was told my injury was complete and I just had to get used to my situation, but I refused to give up.
'I dreamed that one day I might take a few steps and my dream came true.
'About 10 weeks before I finished the trial, I took my first steps just using a walking frame, without any leg supports. Everyone cried.
'I was putting my all into the trial and was being rewarded. Even though it was really slow I could see improvements. My legs were getting stronger and I had hope.
'And although all the gains haven't continued, I definitely think the stimulation had a massive impact on my rehab and I can't wait for it to be licensed in the UK.'
Ms Stewart added: 'This therapy is not a silver bullet – it works on spared spinal tissue so results will vary widely, and it does need to be paired with proper active rehabilitation over a consistent period of time.
'Even so, this is a game changing moment. It's now time to stop talking about spinal cord injury as being incurable and to stop telling people with this injury that nothing can be done.'
Jenny Suggitt, co-investigator of the study, said: 'Participants who have completed the study at this point are seeing changes in their motor function – so their standing ability, walking, core control and sensation changes, as well as changes to their autonomic function – so bladder, bowel and sexual function.
'We are seeing recovery in participants who are over 10 years post injury, and they're regaining function that they never thought possible.'
Co-investigator Jane Symonds said: 'Transcutaneous spinal cord stimulation has been described a little bit like a hearing aid for the nervous system, so it's enhancing the signals that the nervous system is receiving.
'And so it's hoped that if somebody, for example, is trying to get some muscle activity in their legs to be able to stand or walk, that when the stimulation is in place, there is a greater level of excitability in the spinal cord, and therefore those nerve impulses are more likely to reach their target destination, and hopefully enable people to use those muscles.
'It has the potential to be a game changer and we're hoping that it's a real breakthrough for people with spinal cord injury.'
Dave Marver, chief executive of Onward Medical, said the study 'provides critical insights to the spinal cord injury community, demonstrating that improvements resulting from ARC-EX Therapy extend for at least one year, with no observed plateau'.
Harvey Sihota, founder and chief executive of Neurokinex, said: 'There is no doubt that spinal stimulation technology will take spinal cord injury rehab to the next level, bringing even more meaningful functional improvements that offer people greater independence.'
Spinal Research is also funding three other UK studies involving use of implantable and external spinal cord stimulation systems.
Ms Stewart said: 'With proper investment in the spinal research field we could see significant progress towards a cure for paralysis in the next five to seven years.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ONWARD Medical Announces Results of its Annual General Meeting of Shareholders
ONWARD Medical Announces Results of its Annual General Meeting of Shareholders

Yahoo

time7 hours ago

  • Yahoo

ONWARD Medical Announces Results of its Annual General Meeting of Shareholders

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Shareholders approve all proposed resolutions EINDHOVEN, The Netherlands, June 11, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury and other movement disabilities, today announces that that all proposed resolutions at its Annual General Meeting of Shareholders (AGM) were duly passed. The meeting was held this afternoon in Amsterdam, the Netherlands at 4:00PM CET. Full details of the resolutions approved during the AGM can be found on the Company's Investor Relations website. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury (SCI) and other movement disabilities. Building on more than a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). The Company's ARC-EX System is cleared for commercial sale in the US. In addition, the Company is developing an investigational implantable system called ARC-IM with and without an implanted brain-computer interface (BCI). Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). To learn more about ONWARD Medical's commitment to partnering with the spinal cord injury community to develop innovative solutions for restoring movement, function, and independence after spinal cord injury, please visit To be kept informed about the Company's technologies, research studies, and the availability of therapies in your area, please complete this webform. For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Disclaimer Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Trademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited. ARC-EX Indication for Use (US): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive). Other Investigational Products: All other ONWARD Medical devices and therapies including ARC-IM and ARC-BCI are investigational and not available for commercial use.

Mind-controlled prosthetic arms are now becoming a reality
Mind-controlled prosthetic arms are now becoming a reality

Fox News

time14 hours ago

  • Fox News

Mind-controlled prosthetic arms are now becoming a reality

If you've ever wondered what's next for prosthetic technology, you're not alone. For many people living with limb loss, finding a prosthetic that feels natural and works seamlessly with their body has always been a challenge. Now, a California startup called Atom Bodies is making headlines for its groundbreaking approach to prosthetic technology. By combining artificial intelligence, machine learning and advanced sensor systems, Atom Bodies is developing mind-controlled robotic arms that could soon make highly advanced prosthetics accessible to thousands of amputees. Atom Bodies' flagship product, Atom Touch, is setting a new standard in prosthetic arms. Unlike traditional prosthetics, which often offer only basic movement and can be uncomfortable to wear, Atom Touch uses EMG (electromyography) sensors placed on the user's skin to detect muscle activity. These signals are then interpreted by machine-learning algorithms, allowing users to control individual fingers, the wrist and the elbow with remarkable precision just by thinking about the movement they want to make. The arm is powered by the Atom A1, an AI neural interface that can be trained in minutes for intuitive, natural control. The design also includes a load-balanced harness, which distributes weight across the torso, making the device lighter and more comfortable for all-day use. Atom Touch stands out for several reasons. It is the first prosthetic arm to offer true individual finger movement, which means users can perform tasks like typing, gripping and delicate manipulation with much greater ease. The device uses the Atom A1 AI neural interface, which learns from the user's muscle signals to provide seamless, natural movement. Dozens of sensors in the hand generate haptic feedback, so users can better gauge grip strength and control. With more than 10 motors in the hand alone, Atom Touch offers a near-human range of motion and dexterity. The load-balanced harness system also makes the arm lighter than a human arm and comfortable enough for extended wear, addressing a challenge that many current prosthetics have yet to solve. For the more than 2 million Americans living with limb loss, current prosthetic options are often expensive, uncomfortable and limited in capability. Jason Morris, who lost his arm due to a work accident and is Atom Bodies' lead test user, notes that most prosthetics can only be worn for about two hours due to discomfort. Atom Touch is designed for initial wear of four to six hours, with the goal of achieving all-day use. Atom Bodies has already attracted significant interest, with over 11,000 people on its wait list and plans to begin clinical trials within the next year, pending FDA approval. One of the most transformative aspects of Atom Touch is its price point. While state-of-the-art myoelectric arms can cost around $200,000, Atom Bodies plans to offer Atom Touch for approximately $25,000. This brings the cost in line with basic hook prosthetics, making advanced bionic limbs accessible to a much larger population. Seeing Atom Bodies bring this level of innovation to prosthetics feels like a real turning point for people with limb loss. With technology that's both advanced and affordable, Atom Touch could help many regain abilities and comfort that have been out of reach for years. As the company moves closer to launching, there is a sense of real possibility for a future where high-quality prosthetics are available to many more people who need them. If you or someone you know could benefit from this technology, what would be the most important factor in choosing a prosthetic arm? Let us know by writing us at For more of my tech tips and security alerts, subscribe to my free CyberGuy Report Newsletter by heading to Follow Kurt on his social channels: Answers to the most-asked CyberGuy questions: New from Kurt: Copyright 2025 All rights reserved.

ONWARD Medical Schedules Webcast to Provide Q1 2025 Business Update and Year-To-Date Highlights
ONWARD Medical Schedules Webcast to Provide Q1 2025 Business Update and Year-To-Date Highlights

Yahoo

time19 hours ago

  • Yahoo

ONWARD Medical Schedules Webcast to Provide Q1 2025 Business Update and Year-To-Date Highlights

EINDHOVEN, the Netherlands, June 11, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury and other movement disabilities, today announces that it will host a webcast to discuss its Q1 2025 business update and year-to-date highlights. The webcast will be held on June 17, 2025, at 2:00PM CET / 08:00AM ET. It will be hosted by CEO Dave Marver. To join the session, please register using this link. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury (SCI) and other movement disabilities. Building on more than a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). The Company's ARC-EX® System is cleared for commercial sale in the US. In addition, the Company is developing an investigational implantable system called ARC-IM® with and without an implanted brain-computer interface (BCI). Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). To learn more about ONWARD Medical's commitment to partnering with the spinal cord injury community to develop innovative solutions for restoring movement, function, and independence after spinal cord injury, please visit To be kept informed about the Company's technologies, research studies, and the availability of therapies in your area, please complete this webform. For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Disclaimer Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Trademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited. ARC-EX Indication for Use (US): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive). Other Investigational Products: All other ONWARD Medical devices and therapies including ARC-IM and ARC-BCI are investigational and not available for commercial use.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store